Corcoran Gavin
Transaction: 06/05/2026
BUY
Change
+16,000
Price
$6.04
Filing
06/09/2026
Type
BUY
Verrica Pharmaceuticals Inc.
VRCA • Biotechnology
$5.30
▼ -0.06 (-1.12%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$115.05M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.07Healthy liquidity · 2.59Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:55 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$5.30
Change-1.12%
Shares Out21.31M
Market Cap$115.05M
Enterprise Value$105.66M
52W Range3.28 - 9.82
Beta1.49
P/E-3.69
P/S3.79
P/B26.71
P/FCF-5.11
EV/Sales3.48
Price$5.30
Change-1.12%
Shares Out21.31M
Market Cap$115.05M
Enterprise Value$105.66M
52W Range3.28 - 9.82
Beta1.49
P/E-3.69
P/S3.79
P/B26.71
P/FCF-5.11
EV/Sales3.48
EV/EBITDA-3.96
EV/FCF-4.69
Earnings Yield-27.10%
FCF Yield-19.57%
Dividend Yield0.00%
Gross Margin90.33%
Oper. Margin-33.56%
Profit Margin-50.27%
Debt/Eq0.07
Current Ratio2.59
Quick Ratio2.45
Target$9.00
Target Upside69.81%
Target Median$9.00
Target Range9.00 - 9.00
Volume26.86K
Avg Volume52.49K
EPS Surprise0.18
Investment DNA
How strong this company looks for long-term investors
39
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
78/100
Why this score▼
Manageable debt level · 0.07Healthy liquidity · 2.59Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 10 analyst votes · 2026-09-04
80/100
Bullish
Bullish
6
Hold
4
Bearish
0
Price Target
2026-08-13
Low
$10.00
Mean
$13.25
Median
$13.00
High
$17.00
Insider Transactions
Recent executive and insider activity
Rieger Jayson
Transaction: 06/05/2026
BUY
Change
+512,269
Price
$8.21
Filing
06/09/2026
Type
BUY
Zawitz David
Transaction: 06/05/2026
BUY
Change
+171,340
Price
$8.21
Filing
06/09/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Corcoran Gavin | BUY | +16,000 | $6.04 | 06/05/2026 | 06/09/2026 |
| Rieger Jayson | BUY | +512,269 | $8.21 | 06/05/2026 | 06/09/2026 |
| Zawitz David | BUY | +171,340 | $8.21 | 06/05/2026 | 06/09/2026 |
| Rosenberg Noah L. | BUY | +233,840 | $8.21 | 06/05/2026 | 06/09/2026 |
| PRYGOCKI MARK A SR | BUY | +16,000 | $6.04 | 06/05/2026 | 06/09/2026 |
| Nguyen Diem | BUY | +16,000 | $6.04 | 06/05/2026 | 06/09/2026 |
| Eichenfield Lawrence | BUY | +16,000 | $6.04 | 06/05/2026 | 06/09/2026 |
| BKB Growth Investments, LLC | OTHER | +224,719 | $13.35 | 11/25/2025 | 02/02/2026 |
| BKB Growth Investments, LLC | OTHER | +224,719 | $1.33 | 11/25/2025 | 01/26/2026 |
| BKB Growth Investments, LLC | OTHER | +687,690 | $6.32 | 11/25/2025 | 01/26/2026 |
| BKB Growth Investments, LLC | OTHER | 0 | Not reported | 11/25/2025 | 01/26/2026 |
| Frantzreb Charles | OTHER | 0 | Not reported | 12/26/2025 | 12/30/2025 |
| Caligan Partners LP | OTHER | 0 | Not reported | 12/26/2025 | 12/30/2025 |
| Kirby John J. | BUY | +10,000 | Not reported | 12/23/2025 | 12/30/2025 |
| Caligan Partners LP | OTHER | +1,031,559 | $6.32 | 11/25/2025 | 12/30/2025 |
| Caligan Partners LP | OTHER | +4,126,239 | $0.00 | 11/25/2025 | 12/30/2025 |
| Caligan Partners LP | OTHER | +421,346 | $13.35 | 11/22/2024 | 12/30/2025 |
| Manning Paul B | BUY | +343,845 | $6.32 | 11/25/2025 | 11/25/2025 |
| Manning Paul B | BUY | +2,750,762 | $4.24 | 11/25/2025 | 11/25/2025 |
| Rieger Jayson | BUY | +23,577 | $6.32 | 11/25/2025 | 11/25/2025 |